These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31842950)

  • 1. Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study.
    Chen Y; He W; Ouyang H; Liu C; Hong C; Wang T; Yang K; Lu W; Wang J
    Trials; 2019 Dec; 20(1):725. PubMed ID: 31842950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of Propranolol in Resistant Arterial hypertension Treatment (APROPRIATE study): study protocol for a randomized double-blind placebo-controlled trial.
    Constantine GR; Ranasinghe P; Weeratunga P; Weeraratne C; Galappatthy P; Rajapakse S; Senarath U; Katulanda P
    Trials; 2017 Mar; 18(1):124. PubMed ID: 28292320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
    Sitbon O; Vonk Noordegraaf A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.
    Beghetti M; Rudzinski A; Zhang M
    BMC Cardiovasc Disord; 2017 Jul; 17(1):177. PubMed ID: 28676038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease.
    Faria-Urbina M; Oliveira RKF; Agarwal M; Waxman AB
    Lung; 2018 Apr; 196(2):139-146. PubMed ID: 29275453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized pilot study on the effect of niacin on pulmonary arterial pressure.
    McNamara MJ; Sayanlar JJ; Dooley DJ; Srichai MB; Taylor AJ
    Trials; 2015 Nov; 16():530. PubMed ID: 26590128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pulmonary hypertension with left heart disease: a concise review.
    Desai A; Desouza SA
    Vasc Health Risk Manag; 2017; 13():415-420. PubMed ID: 29158679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.
    Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG;
    Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
    Ogawa A; Miyaji K; Yamadori I; Shinno Y; Miura A; Kusano KF; Ito H; Date H; Matsubara H
    Circ J; 2012; 76(7):1729-36. PubMed ID: 22481098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
    Langleben D; Brock T; Dixon R; Barst R;
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.
    Mathijssen H; Huitema MP; Bakker ALM; Mager JJ; Snijder RJ; Grutters JC; Post MC
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(1):74-78. PubMed ID: 33093771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension.
    Chen Y; Lu W; Yang K; Duan X; Li M; Chen X; Zhang J; Kuang M; Liu S; Wu X; Zou G; Liu C; Hong C; He W; Liao J; Hou C; Zhang Z; Zheng Q; Chen J; Zhang N; Tang H; Vanderpool RR; Desai AA; Rischard F; Black SM; Garcia JGN; Makino A; Yuan JX; Zhong N; Wang J
    Br J Pharmacol; 2020 Jun; 177(12):2743-2764. PubMed ID: 31976548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
    Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM
    Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.